TMFX - ETF AI Analysis
Top Page
Motley Fool Next Index ETF (TMFX)
Rating:69Neutral
Price Target:―
Positive Factors
Broad Sector Diversification
The fund spreads its investments across many sectors, which can help reduce the impact if any one industry struggles.
Recent Positive Performance
The ETF has shown steady gains over the past month and year-to-date, suggesting its strategy has been working recently.
Multiple Strong Individual Holdings
Several top positions, such as Casey's General, Twilio, Dexcom, Biogen, and Cboe Global Markets, have delivered strong recent performance that supports the fund’s returns.
Negative Factors
High U.S.-Only Concentration
Almost all of the fund’s assets are invested in U.S. companies, offering little geographic diversification if the U.S. market weakens.
Several Weak Top Holdings
Some of the largest positions, including Workday, Reddit, Coupang, Veeva Systems, and EQT, have shown weak recent performance, which can drag on overall results.
Moderately High Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, meaning more of the returns are used to cover fees instead of going to investors.
TMFX vs. SPDR S&P 500 ETF (SPY)
AUM33.32M
RegionNorth America
Expense Ratio0.50%
Beta1.07
IssuerMotley Fool
Inception DateDec 29, 2021
Dividend Yield0.05%
Asset ClassEquity
Index TrackedMotley Fool Next Index - Benchmark TR Gross
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume5,302
30 Day Avg. Volume5,160
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
26.96Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering197
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TMFX Summary
TMFX, the Motley Fool Next Index ETF, follows the Motley Fool Next Index, which focuses on mid-size and smaller U.S. companies outside the usual large-cap names. It spreads investments across technology, health care, consumer, and industrial businesses, aiming to find future leaders with strong growth potential. Well-known holdings include Workday and Reddit. Someone might invest in TMFX to diversify beyond big, established companies and seek higher long-term growth from up-and-coming firms. A key risk is that smaller and growth-focused stocks can be more volatile, so the ETF’s value can rise and fall sharply with market conditions.
How much will it cost me?The Motley Fool Next Index ETF (TMFX) has an expense ratio of 0.50%, meaning you’ll pay $5 per year for every $1,000 invested. This is higher than average for ETFs because it is actively managed, focusing on identifying high-growth and innovative companies rather than tracking a broad index. Active management typically involves more research and strategy, which increases costs.
What would affect this ETF?The TMFX ETF, which focuses on mid-cap and small-cap companies in the U.S., could benefit from growth in innovative sectors like technology and health care, as these industries often drive market disruption and long-term expansion. However, its exposure to consumer cyclical and financial sectors may face challenges during economic downturns or periods of high interest rates, which can impact consumer spending and borrowing. Additionally, regulatory changes or shifts in market sentiment toward smaller companies could influence the ETF's performance positively or negatively.
TMFX Top 10 Holdings
TMFX leans heavily into U.S. mid- and small-cap innovators, with health care and tech doing much of the heavy lifting. Biogen and Dexcom have been steady climbers, helping support returns, while Casey’s General Stores adds a more defensive, consumer tilt that’s quietly rising. On the flip side, Workday and Veeva are losing steam despite solid business stories, and Coupang’s slump has been a noticeable drag. Overall, the fund is a U.S.-centric bet on emerging growth names, with a clear tilt toward disruptive health care and tech platforms.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Workday | 1.92% | $628.53K | $39.60B | -26.68% | 73 Outperform | |
| Casey's General | 1.62% | $533.05K | $32.23B | 64.43% | 68 Neutral | |
| Cboe Global Markets | 1.62% | $531.11K | $32.47B | 18.72% | 75 Outperform | |
| EQT | 1.59% | $522.77K | $33.33B | 3.26% | 76 Outperform | |
| Dexcom | 1.58% | $519.89K | $31.49B | 14.50% | 79 Outperform | |
| Veeva Systems | 1.50% | $492.74K | $33.10B | -27.70% | 66 Neutral | |
| Biogen | 1.43% | $470.24K | $29.99B | 52.66% | 74 Outperform | |
| Resmed | 1.43% | $468.80K | $30.60B | -26.16% | 76 Outperform | |
| GE Healthcare Technologies Inc | 1.43% | $468.39K | $30.72B | -1.29% | 78 Outperform | |
| Coupang | 1.42% | $465.98K | $29.35B | -44.58% | 60 Neutral |
TMFX Technical Analysis
Positive
―
Price Trends
22.71
Positive
21.75
Positive
21.65
Positive
Market Momentum
0.26
Negative
63.94
Neutral
89.47
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For TMFX, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 23.13, equal to the 50-day MA of 22.71, and equal to the 200-day MA of 21.65, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 63.94 is Neutral, neither overbought nor oversold. The STOCH value of 89.47 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TMFX.
TMFX Peer Comparison
Comparison Results
Performance Comparison
TMFX
Motley Fool Next Index ETF
23.84
2.99
14.34%
OASC
OneAscent Small Cap Core ETF
―
―
―
FSCS
First Trust Smid Capital Strength Etf
―
―
―
HSMV
First Trust Horizon Managed Volatility Small/Mid ETF
―
―
―
MYLD
Cambria Micro and SmallCap Shareholder Yield ETF
―
―
―
BCSM
Baron SMID Cap ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents